Latest revenue
$696.6M
as of 2026-03-31
Latest net income
$-85.1M
as of 2026-03-31
Net margin
-12.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $29.10B
- Enterprise value
- $29.10B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $256.36
- 52-wk low
- $131.81
- Beta
- —
- Shares out
- 143.2M
5-year trend
What this company does
Item 1.BUSINESS Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. Overview We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. We aim to make personalized genetic testing and…
AI summary unavailable — showing raw filing excerpt
Generated from NTRA's filing dated 2026-02-27
Key risks
ITEM 1A.RISK FACTORS Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this report, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks actually occurs, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the price of…
AI summary unavailable — showing raw filing excerpt
Generated from NTRA's filing dated 2026-02-27
Profitability
Operating margin
-13.4%
2.6%Net margin
-9.0%
19.6%Return on equity
-12.2%
23.7%Return on assets
-8.7%
24.3%Leverage
Debt / equity
0.40×
2.9%Long-term debt / equity
0.37×
7.4%Debt / assets
28.6%
2.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $696.6M | +38.8% | $-85.1M | -27.1% | -12.2% |
Q4 2025 2025-12-31 | $665.5M | +39.8% | $47.3M | +187.9% | 7.1% |
Q3 2025 2025-09-30 | $592.2M | +34.7% | $-87.5M | -177.1% | -14.8% |
Q2 2025 2025-06-30 | $546.6M | +32.2% | $-100.9M | -169.4% | -18.5% |
Q1 2025 2025-03-31 | $501.8M | +36.5% | $-66.9M | +1.0% | -13.3% |
Q4 2024 2024-12-31 | $476.1M | — | $-53.8M | — | -11.3% |
Q3 2024 2024-09-30 | $439.8M | +63.9% | $-31.6M | +71.0% | -7.2% |
Q2 2024 2024-06-30 | $413.4M | +58.1% | $-37.5M | +66.2% | -9.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on NTRA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$260.7M
Net activity
−$260.7M
Distinct insiders
12
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns NTRA
Institutional value
$12.14B
Total shares held
62.4M
Distinct holders
495
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JPMORGAN CHASE & CO | 13.4M | $2.50B | — | New |
| 2 | BlackRock, Inc. | 10.7M | $2.14B | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $1.20B | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.6M | $1.13B | — | New |
| 5 | FRANKLIN RESOURCES INC | 2.5M | $497.0M | — | New |
| 6 | Capital World Investors | 1.5M | $293.6M | — | New |
| 7 | Invesco Ltd. | 1.3M | $251.7M | — | New |
| 8 | FEDERATED HERMES, INC. | 1.1M | $218.0M | — | New |
| 9 | Clearbridge Investments, LLC | 893.3K | $178.7M | — | New |
| 10 | VANGUARD FIDUCIARY TRUST CO | 872.6K | $174.5M | — | New |
| 11 | WESTFIELD CAPITAL MANAGEMENT CO LP | 754.7K | $150.9M | — | New |
| 12 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 752.9K | $150.6M | — | New |
| 13 | Sumitomo Mitsui Trust Group, Inc. | 692.4K | $138.5M | — | New |
| 14 | ARK Investment Management LLC | 684.3K | $136.8M | — | New |
| 15 | Bank of New York Mellon Corp | 669.7K | $133.9M | — | New |
| 16 | FIRST TRUST ADVISORS LP | 528.8K | $105.8M | — | New |
| 17 | Legal & General Group Plc | 498.1K | $99.6M | — | New |
| 18 | AGF MANAGEMENT LTD | 491.3K | $98.2M | — | New |
| 19 | Nuveen, LLC | 474.6K | $94.9M | — | New |
| 20 | Allspring Global Investments Holdings, LLC | 463.5K | $94.2M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once NTRA's latest filing finishes processing.